Digoxin-drug interactions: study design and generalizability.
Li Wan Po
A
A
Centre for Evidence-Based Pharmacotherapy, Aston University, Aston Triangle, Birmingham B4 7ET, UK. a.liwanpo@aston.ac.uk
D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D015982:Bias; D004077:Digoxin / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D004347:Drug Interactions; D006304:Health Status; D006801:Humans; D015242:Ofloxacin / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D018579:Patient Selection; D016032:Randomized Controlled Trials as Topic; D015203:Reproducibility of Results; D012107:Research Design; D013449:Sulfonamides / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D000077409:Tamsulosin
D000317:Adrenergic alpha-Antagonists; D000889:Anti-Arrhythmia Agents; D000890:Anti-Infective Agents; D013449:Sulfonamides; D004077:Digoxin; D015242:Ofloxacin; D000077409:Tamsulosin